Cerenome stock analysis
Want to see CNSY full AI Analyst Report?
Cerenome (CNSY) Stock Price & Analysis
CNSY Stock Chart & Stats
- Day’s Range
- $0.81 - $1.18
- 52-Week Range
- $0.43 - $18.90
- Previous Close
- $0.77
- Volume
- N/A
- Average Volume (3M)
- 1.51M
- Market Cap
- $7.21M
- Enterprise Value
- $13.26M
- Total Cash (Recent Filing)
- $4.87M
- Total Debt (Recent Filing)
- $3.98M
- Price to Earnings (P/E)
- 0.0
- Beta
- 2.40
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin
The roughly 90% TTM gross margin indicates strong product-level economics and suggests the core offering can generate substantial contribution after direct costs. If revenue scales, this margin profile could support operating leverage, although current overhead still prevents profitability.
Commercial Expansion
Planned sales expansion, billing activity, and Medicare reimbursement create identifiable pathways to broaden CNSide revenue. These milestones could improve market access and commercial execution over the next several quarters, making growth less dependent on existing activity.
Funding Runway
Extending the expected cash runway well into 2028 gives Cerenome additional time to develop its CNS oncology platform, pursue commercialization, and reach operational milestones. More funding continuity can reduce near-term disruption risk while sales initiatives mature.
Bears Say
Declining Revenue
Very small and declining revenue shows that Cerenome has not yet achieved meaningful commercial scale. Persistent top-line contraction limits operating leverage, makes fixed spending harder to absorb, and increases dependence on successful future commercialization milestones.
Losses And Cash Burn
Large losses alongside deeply negative operating and free cash flow indicate that the business is consuming substantial capital relative to its revenue base. Unless spending falls or revenue scales materially, continued cash usage will constrain flexibility and require further funding.
Balance Sheet Pressure
Negative equity weakens financial resilience, while secured financing adds contractual repayment pressure and places substantially all assets behind creditors. The combination can restrict future capital allocation and increase refinancing or dilution risk if commercialization takes longer than planned.
CNSY FAQ
What was Cerenome’s price range in the past 12 months?
What is Cerenome’s market cap?
When is Cerenome’s upcoming earnings report date?
How were Cerenome’s earnings last quarter?
Is Cerenome overvalued?
Does Cerenome pay dividends?
What is Cerenome’s EPS estimate?
How many shares outstanding does Cerenome have?
What happened to Cerenome’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cerenome?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Cerenome
Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Marc H. Hedrick
- Employees
- 28
- Website
- cerenome.com
- Address
- 6420 Levit Green Blvd, Houston, TX, 77021, US
Cerenome (CNSY) Earnings & Revenues
CNSY Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 4 | 10 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 4 | 0 | 8 |









